Reviewer’s report

Title: AJCC 8th Edition Prognostic Staging provides no better discriminatory ability in prognosis than Anatomical Staging in triple negative breast cancer

Version: 0 Date: 29 Nov 2019

Reviewer: Naoki Kanomata

Reviewer's report:

The comparison of AJCC AS and PS for triple negative breast cancers was reported. This is an interesting manuscript.

1. In Statistical Analysis, "Cases with nuclear grade of grade III and IV in SEER cohort were both classified as G3 in PS system" AJCC uses histologic grade, not nuclear grade. The reanalyses using histologic grade should be done.
2. What histologic types were rare to be excluded in SYSUCC and PWH cases? Was only invasive carcinoma, NST evaluated?
3. In SEER cohort, were all histologic types used?
4. BRCA status would be interesting to be analysed.
5. "No case was classified as anatomic stage IB in this cohort" seems strange. No cytokeratin immunohistochemistry was done?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Unable to assess

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Unable to assess

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal